Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation

摘要: Introduction Haematopoietic stem cell transplantation (HSCT) is commonly employed in the management of haematological malignancies. This intervention results an increased risk infectious and immune-related complications. Prophylactic immunoglobulin therapy has been used to prevent post-HSCT complications, including infections, with varying efficacy. We sought update current evidence supporting use immunoglobulins modern HSCT era. Methods/analysis Using a structured search strategy, we will perform systematic review literature from MEDLINE, EMBASE all EBM Reviews databases. include randomised clinical trials investigating outcomes prophylactic polyvalent or cytomegalovirus (CMV)-specific plasma patients undergoing HSCT. Clinical overall survival, transplant-related mortality, CMV infection, disease, graft-versus-host interstitial pneumonitis/fibrosis hepatic veno-occlusive disease. Studies that only reported biochemical tests be excluded. Data extracted by two investigators independently. Study quality assessment evaluated using validated five-point system as proposed Jadad. Trial further assessed identifying whether there was adequate allocation concealment. Where appropriate, meta-analysis performed where relative primary summary measure 95% CIs. Pooled measures calculated for random-effects model. The Cochrane Q/χ2 test I2 statistic also evaluate heterogeneity. visual inspection funnel plot assess potential publication bias. Discussion aims provide justify prophylaxis recipients. discuss guidelines are supported evidence, needed, given changing landscape manufacturing process. Systematic registration PROSPERO CRD42015016684.